PEPTONIC medical AB (publ) (XSAT:PMED)
0.0600
0.00 (0.00%)
At close: Jan 31, 2024
PEPTONIC medical AB Revenue
PEPTONIC medical AB had revenue of 3.40M SEK in the quarter ending March 31, 2026, a decrease of -9.73%. This brings the company's revenue in the last twelve months to 26.39M, up 30.43% year-over-year. In the year 2025, PEPTONIC medical AB had annual revenue of 26.75M, down -3.13%.
Revenue (ttm)
26.39M
Revenue Growth
+30.43%
P/S Ratio
6.50
Revenue / Employee
7.08M
Employees
2
Market Cap
92.09M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.75M | -865.00K | -3.13% |
| Dec 31, 2024 | 27.62M | -10.65M | -27.83% |
| Dec 31, 2023 | 38.27M | -8.14M | -17.54% |
| Dec 31, 2022 | 46.40M | 14.14M | 43.82% |
| Dec 31, 2021 | 32.27M | 9.83M | 43.82% |
| Dec 31, 2020 | 22.43M | 17.96M | 401.65% |
| Dec 31, 2019 | 4.47M | 4.00M | 853.52% |
| Dec 31, 2018 | 469.00K | 300.00K | 177.51% |
| Dec 31, 2017 | 169.00K | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 10.00K | - | - |
| Dec 31, 2013 | 0 | - | - |
| Dec 31, 2012 | 43.01M | 42.51M | 8,501.00% |
| Dec 31, 2011 | 500.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bergholm Holding AB | 593.52M |
| Gullberg & Jansson AB | 261.44M |
| Mendole | 189.92M |
| SolidX AB | 137.67M |
| QBNK Holding AB | 40.26M |
| Redsense Medical AB | 28.70M |
| Touchtech AB | 23.01M |
| AcuCort AB | 7.44M |
PEPTONIC medical AB News
- 2 months ago - PEPTONIC medical AB Quarterly report: Q1 2026 - Filings
- 5 months ago - PEPTONIC medical AB Quarterly report: Q4 2025 - Filings
- 5 months ago - PEPTONIC medical AB Annual report: Q4 2025 - Filings
- 9 months ago - PEPTONIC medical AB Quarterly report: Q3 2025 - Filings
- 1 year ago - PEPTONIC medical AB Quarterly report: Q2 2025 - Filings